|
im derzeitigen Börsenimfeld auch mal schön, wenn man auf einen Edelstein aufmerksam gemacht wird GenVec to Present at the BIO Investor Forum Download image GAITHERSBURG, Md., Oct. 22 /PRNewswire-FirstCall/ -- Today GenVec, Inc. (Nasdaq: GNVC) announced that Paul H. Fischer, Ph.D., President and CEO, will present a company overview highlighting recent developments at the BIO Investor Forum on Thursday, October 29, 2009 at 12:00 pm PST at The Palace Hotel in San Francisco, CA. (Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) A webcast of Dr. Fischer's presentation will be available both live and on replay. To access either the live or archived webcast, log on to GenVec's website at www.genvec.com, click on "Investor Relations," and proceed to "Webcasts & Data." The replay will be available 24 hours after the live presentation and will be accessible for 30 days. About GenVec GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission. Investor Contact: Media Contact: GenVec, Inc. Tiberend Strategic Advisors, Inc. Danielle M. DiPirro Andrew Mielach (301) 944-1877 (212) 827-0020 ddipirro@genvec.com amielach@tiberendstrategicadvisors.com SOURCE GenVec, Inc. |
|
| aus der Diskussion: | Neue Erkenntnisse für einen Impfstoff gegen alle HIV-Suptypen |
| Autor (Datum des Eintrages): | dottore (22.10.09 16:51:26) |
| Beitrag: | 15 von 17 (ID:38233369) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |